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Background: We hypothesized that patients undergoing surgery for colorectal cancer (CRC) 
with COPD as a comorbidity would consume more resources and have worse in-hospital 
outcomes than similar patients without COPD. Therefore, we compared different aspects of 
the care process and short-term outcomes in patients undergoing surgery for CRC, with and 
without COPD.
Methods: This was a prospective study and it included patients from 22 hospitals located in 
Spain – 472 patients with COPD and 2,276 patients without COPD undergoing surgery for 
CRC. Clinical variables, postintervention intensive care unit (ICU) admission, use of invasive 
mechanical ventilation, and postintervention antibiotic treatment or blood transfusion were 
compared between the two groups. The reintervention rate, presence and type of complications, 
length of stay, and in-hospital mortality were also estimated. Hazard ratio (HR) for hospital 
mortality was estimated by Cox regression models.
Results: COPD was associated with higher rates of in-hospital complications, ICU admission, 
antibiotic treatment, reinterventions, and mortality. Moreover, after adjusting for other factors, 
COPD remained clearly associated with higher and earlier in-hospital mortality.
Conclusion: To reduce in-hospital morbidity and mortality in patients undergoing surgery for 
CRC and with COPD as a comorbidity, several aspects of perioperative management should be 
optimized and attention should be given to the usual comorbidities in these patients.
Keywords: COPD, colorectal cancer, in-hospital mortality, reintervention, complications
Introduction
Colorectal cancer (CRC), one of the most common cancers in developed countries, 
has a 5-year survival rate of about 60%.1–3 Most patients are diagnosed at a relatively 
advanced age, when chronic comorbidities are often present. COPD is prevalent and 
commonly associated with other diseases.4,5
Surgery is essential in many cases of CRC and is associated with considerable 
mortality (up to 11% at 30 days) and a high rate of complications.6,7 Many factors 
are associated with outcomes after different types of surgery, and COPD has been 
associated with increased short-term mortality. However, few studies of postopera-
tive outcomes in patients with COPD focus on patients with CRC or on postoperative 
outcomes other than mortality, such as reintervention, complications, or length of stay 
(LOS).8 Recently, Platon et al9 found COPD was a strong predictor of intensive care 
unit (ICU) admission and 30-day mortality after CRC surgery.9
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Poorer outcomes after surgery in patients with COPD are 
related to respiratory failure or other postoperative compli-
cations, which can lead to higher short-term mortality. In 
patients undergoing abdominal surgery, the most common 
short-term complications include not only infection or other 
complications involving the site of surgery but also organ 
failure, including respiratory failure or ventilator problems. 
In patients with COPD, respiratory complications are prob-
ably even more common, adding complexity to immediate 
postoperative management and increasing the likelihood of 
worse outcomes.
Despite the prevalence and importance of COPD, few 
studies have analyzed the overall impact of COPD on post-
operative (in-hospital) outcomes or on the use of resources 
in oncologic surgery in general or CRC surgery in particular. 
We hypothesized that patients undergoing surgery for CRC 
with COPD as a comorbidity would consume more resources 
and have worse in-hospital outcomes than similar patients 
without COPD. To test this hypothesis, we compared some 
aspects of the care process and short-term outcomes in two 
cohorts of patients (with and without COPD) undergoing 
surgery for CRC in diverse hospitals in Spain.
Methods
Design and patients
This prospective multicenter cohort study of patients from 
22 hospitals located in nine regions of Spain was done in 
the framework of the REDISSEC-CARESS/CCR (Results 
and Health Services Research in Colorectal Cancer) study, 
which addressed diverse research objectives in hospitals 
treating CRC in Spain for the national health system.10 The 
hospitals’ size and technological resources varied widely. 
The Clinical Research Ethics Committees of the Parc Taulí 
Sabadell-University Hospital; Hospital del Mar; Fundació 
Unio Catalana d’Hospitals; Gipuzkoa Health Area; Basque 
Country; Hospital Galdakao-Usansolo; Hospital Txagorritxu; 
La Paz University Hospital; Fundación Alcorcón University 
Hospital; Hospital Universitario Clínico San Carlos (formerly 
Clinical Research Ethics Committee of Area 7 – Hospital 
Clínico San Carlos); and the Regional Clinical Research 
Ethics Committee of Andalusia approved the study. All 
patients provided written informed consent.
We included patients undergoing scheduled or urgent sur-
gery for primary invasive CRC in the period from June 2010 
through December 2012, whether the goal of surgery was to 
excise the tumor or to palliate symptoms.
The REDISSEC-CARESS/CCR study excluded patients 
with only cancer in situ, those with relapsed tumors, those 
with cancer not located in the colon or rectum, those who 
died before surgery, those with inoperable cancer, and those 
transferred for surgery in another center.
Variables and data collection
Appropriately trained reviewers used a structured questionnaire 
and a manual to collect data from clinical records and inter-
views with surgeons about the following clinical variables: age, 
categorized as ,80 years or $80 years; sex; smoking habit; 
chronic alcoholism; body mass index (BMI), calculated from 
the weight and height recorded in the clinical history, with 
BMI ,18.5 considered low, 18.5–25 normal, and BMI .25 
overweight/obese; baseline comorbidities included in the 
Charlson Index, with Charlson scores classified in three 
categories (0, 1–2, $3); tumor location (colon or rectum); 
American Society of Anesthesiologists (ASA) score (I–IV); 
urgency of the intervention; type of surgery (laparoscopic or 
open); and staging according to the AJCC.11
COPD (eg, emphysema and chronic bronchitis) was con-
sidered present when the diagnosis was mentioned in patients’ 
clinical charts. Asthma or other acute or chronic inflamma-
tory diseases of the airways resulting in bronchospasm alone 
were not considered COPD. Likewise, diffuse interstitial 
fibrosis or sarcoidosis was not considered COPD.
We recorded the following process variables: postint-
ervention ICU admission, use of invasive mechanical ven-
tilation, and postintervention antibiotic treatment or blood 
transfusion.
Outcome variables were reintervention, major compli-
cations during the intervention, complications during the 
hospital stay (as described in Quintana et al10), and the LOS 
after the intervention grouped into four ranges (1–7 days, 
8–15 days, 16–30 days, .30 days). For the purposes of this 
study, complications were classified by severity into three 
mutually exclusive categories (none, minor, major) according 
to the clinical judgment of the surgeons participating in 
the study, with major complications classified by type 
(infectious, hemorrhagic, surgical, vascular, or medical). 
In-hospital mortality was defined as any death occurring 
before discharge from hospital, independently of the duration 
of the hospital LOS.
Data analyses
A descriptive analysis of all variables was carried out. To 
compare patients with COPD versus those without COPD, 
we used chi-square tests or Fisher’s exact test for categorical 
variables. For process and outcome variables, we also 
estimated crude odds ratios (OR) with 95% confidence 
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intervals (CI). We used logistic regression techniques, 
incorporating statistically or clinically significant variables 
in the bivariate analysis to estimate the adjusted risk of 
death during the hospital stay. To adjust for comorbidities, 
we took the Charlson scores into account. Thus, in addition 
to the variable COPD, the final regression model included 
the other significant variables that enabled the maximum 
discriminatory capacity of the model estimated by the area 
under the receiver operating characteristic curve with good 
calibration according to the Hosmer–Lemeshow test.
To estimate the probability of in-hospital death in func-
tion of the presence of COPD, we used Kaplan–Meier 
survival analysis, in which discharge was considered a cen-
soring event. We compared the survival curves of patients 
with COPD versus those without COPD by log-rank test. 
We used Cox regression models to estimate the hazard ratio 
(HR) for hospital mortality, adjusted for the same factors or 
variables as in the logistic regression model.
We defined statistical significance as P,0.05, and 
we used IBM Statistical Package for the Social Sciences 
(SPSS)  Statistics 23 and R statistical package 2.15.3 for 
the analyses.
Results
We analyzed a total of 2,748 patients with CRC (mean 
age, 68 years); of these, 472 (17.2%) had COPD. Table 1 
compares the sociodemographic and clinical variables in 
patients with COPD versus those without COPD. The COPD 
group had higher proportions of men (80.5% vs 60.1%, 
P,0.001), patients aged $80 years (25.8% vs 14.7%, 
P,0.001), patients with chronic alcoholism (22.1% vs 
11%, P,0.001), and patients with smoking habit (18.6% vs 
12.2%, P,0.001). Moreover, Charlson scores were higher 
in patients with COPD because comorbidities were more 
common. Specifically, the following comorbidities were 
more common in patients with COPD than in those without 
COPD: heart failure (20% vs 7.6%, P,0.001), diabetes (26% 
vs 18%, P,0.001), peripheral vascular disease (10.9% vs 
4%, P,0.001), peptic ulcers (11.4% vs 4.8%, P,0.001), 
and primary malignant tumors other than CRC (11.3% vs 
6.7%, P,0.001). The most common comorbidities in patients 
with COPD were diabetes mellitus (25.8%), moderate to 
severe heart failure (20.3%), peptic ulcer (11.5%), malignant 
primary tumors other than CRC (11.3%), and peripheral 
vascular disease (10.9%).
No differences were observed between patients with 
COPD and those without COPD in the urgency of the inter-
vention, CRC location, or CRC stage. Laparoscopic surgery 
Table 1 sociodemographic and clinical variables in patients with 






n % n %
sex ,0.001
Male 1,368 60.1 380 80.5
Female 908 39.9 92 19.5
age (years) ,0.001
,80 1,937 85.3 350 74.2
$80 335 14.7 122 25.8
Chronic alcoholism ,0.001
no 1,915 89.0 352 77.9
Yes 237 11.0 100 22.1
smoking habit ,0.001
no 1,980 87.8 376 81.4












Overweight/obesity 1,202 69.2 266 70.6
Comorbidities
Charlson Index ,0.001
0 1,913 84.1 322 68.7
1–2 299 13.1 124 26.4
$3 64 2.8 23 4.9
Ischemic heart disease 0.004
no 2,166 95.3 431 92.1
Yes 106 4.7 37 7.9
heart failure (moderate/severe) ,0.001
no 2,104 92.4 376 79.7
Yes 172 7.6 96 20.3
Peripheral vascular disease ,0.001
no 2,186 96.0 418 89.1
Yes 90 4.0 51 10.9
Cerebrovascular disease 0.299
no 2,175 95.6 443 94.5
Yes 101 4.4 26 5.5
Dementia 0.301
no 2,258 99.2 463 98.7
Yes 18 0.8 6 1.3
Peptic ulcer ,0.001
no 2,165 95.2 415 88.5
Yes 110 4.8 54 11.5
Connective tissue disease 1.000
no 2,267 99.6 467 99.6
Yes 9 0.4 2 0.4
liver disease ,0.001
no 2,226 97.8 443 94.5
Yes 50 2.2 26 5.5
Diabetes ,0.001
no 1,866 82.0 348 74.2
Yes 410 18.0 121 25.8
renal failure (moderate/severe) 0.079
no 2,225 97.8 452 96.4
Yes 51 2.2 17 3.6
(Continued)





Table 2 Process and outcome variables in patients with COPD 
versus in those without, 2010–2012





n % n %
Complications
severity of complications ,0.001
no 1,193 52.4 177 37.5
Minor 481 21.1 114 24.2 1.597 (1.234–2.068)
Major 602 26.4 181 38.3 2.027 (1.611–2.549)
Infectious (major) ,0.001
no 2,021 88.8 388 82.2
Yes 255 11.2 84 17.8 1.716 (1.311–2.246)
hemorrhagic (major) 0.286
no 2,159 94.9 442 93.6
Yes 117 5.1 30 6.4 1.252 (0.828–1.895)
surgical (major) ,0.001
no 2,004 88.0 380 80.5
Yes 272 12.0 92 19.5 1.784 (1.375–2.315)
Vascular (major) 0.035
no 2,166 95.2 438 92.8
Yes 110 4.8 34 7.2 1.529 (1.027–2.276)
Medical (major) ,0.001
no 2,141 94.1 409 86.7
Yes 135 5.9 63 13.3 2.443 (1.779–3.355)
Use of resources
Intensive care unit admission ,0.001
no 1,743 76.6 325 68.9
Yes 533 23.4 147 31.1 1.479 (1.190–1.839)
Invasive mechanical ventilation 0.027
no 2,221 97.6 452 95.8
Yes 55 2.4 20 4.2 1.787 (1.061–3.011)
In-hospital antibiotic treatment  
(postintervention)
0.001
no 1,274 56.0 223 47.2
Yes 1,002 44.0 249 52.8 1.420 (1.164–1.732)
Blood transfusion 0.444
no 1,702 74.8 345 73.1
Yes 574 25.2 127 26.9 1.092 (0.872–1.366)
reintervention 0.010
no 2,106 92.5 420 89.0
Yes 170 7.5 52 11.0 1.534 (1.105–2.129)
Postintervention lOs (days) ,0.001
1–7 1,104 48.5 164 34.7
8–15 799 35.1 194 41.1 1.634 (1.303–2.051)
16–30 278 12.2 78 16.5 1.889 (1.399–2.549)
.30 93 4.1 36 7.6 2.606 (1.715–3.959)
In-hospital death ,0.001
no 2,256 99.1 451 95.6
Yes 20 0.9 21 4.4 5.252 (2.824–9.770)
Abbreviations: LOS, length of stay; OR, odds ratio; 95% CI, 95% confidence interval.
and in those without. The infectious complications that were 
more common in patients with COPD than in those with-
out were pneumonia and other respiratory tract infections, 
intravenous catheter infections, and septic shock. The main 







n % n %
hemiplegia 0.305
no 2,265 99.5 465 99.1
Yes 11 0.5 4 0.9
leukemia, lymphoma, or any other tumor (past 5 years) 0.001
no 2,124 93.3 416 88.7
Yes 152 6.7 53 11.3
Metastatic solid tumor (different from colorectal cancer) 0.238
no 2,256 99.1 468 99.8
Yes 20 0.9 1 0.2
aIDs –
no 2,276 100.0 469 100.0
Yes 0 0.0 0 0.0
asa score ,0.001
I–II 1,402 63.4 145 31.5
III 751 34.0 269 58.5
IV 59 2.7 46 10.0
Tumor and intervention
location 0.554
Colon 1,633 71.7 345 73.1
rectum 643 28.3 127 26.9
stage 0.193
I 501 22.1 125 26.7
II 798 35.2 156 33.3
III 749 33.1 143 30.6
IV 216 9.5 44 9.4
Urgency of intervention 0.302
no 2,197 96.5 451 95.6
Yes 79 3.5 21 4.4
Type of surgery 0.001
laparoscopic 1,342 59.6 237 50.9
Open 910 40.4 229 49.1
Abbreviations: BMI, body mass index; asa, american society of anesthesiologists.
was less common in patients with COPD (50.9% vs 59.6%, 
P,0.001). A greater proportion of patients with COPD were 
classified under ASA III (58.5% vs 34%, P,0.001) and IV 
(10% vs 2.7%, P,0.001) risk categories.
Table 2 compares the process and outcome variables in 
patients with COPD versus those without COPD.
A greater proportion of patients with COPD developed 
complications during the hospital stay (62.5% in patients 
with COPD vs 47.5% in those without, P,0.001); likewise, 
a greater proportion of patients with COPD developed 
more severe complications (38.3% in patients with COPD 
vs 26.4% in those without, P,0.001). Major infectious, 
surgical, vascular, and medical complications were more 
common in patients with COPD. Table 3 reports the frequen-
cies of specific major complications in patients with COPD 
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No (N=2,276) Yes (N=472)
N %Col N %Col
Infectious ,0.001
no 2,021 88.8 388 82.2
Yes 255 11.2 84 17.8
Pneumonia 0.018
no 2,250 98.9 460 97.5
Yes 26 1.1 12 2.5
Catheter infection 0.006
no 2,235 98.2 454 96.2
Yes 41 1.8 18 3.8
sepsis 0.158
no 2,266 99.6 467 98.9
Yes 10 0.4 5 1.1
septic shock 0.030
no 2,224 97.7 453 96.0
Yes 52 2.3 19 4.0
localized intra-abdominal infection (abscess) 0.341
no 2,204 96.8 453 96.0
Yes 72 3.2 19 4.0
Peritonitis 0.036
no 2,212 97.2 450 95.3
Yes 64 2.8 22 4.7
Deep surgical infection 0.705
no 2,211 97.1 457 96.8
Yes 65 2.9 15 3.2
respiratory tract infection 0.001
no 2,266 99.6 462 97.9
Yes 10 0.4 10 2.1
Hemorrhagic complication 0.286
no 2,159 94.9 442 93.6
Yes 117 5.1 30 6.4
Bleeding wound 0.905
no 2,225 97.8 461 97.7
Yes 51 2.2 11 2.3
Internal bleeding of other organs 0.074
no 2,222 97.6 454 96.2
Yes 54 2.4 18 3.8
hemoperitoneum 0.309
no 2,255 99.1 465 98.5
Yes 21 0.9 7 1.5
Surgical complication ,0.001
no 2,004 88.0 380 80.5
Yes 272 12.0 92 19.5
Wound leakage 0.007
no 2,214 97.3 448 94.9
Yes 62 2.7 24 5.1
anastomotic leakage 0.022
no 2,193 96.4 444 94.1
Yes 83 3.6 28 5.9
evisceration 0.003
no 2,250 98.9 458 97.0
Yes 26 1.1 14 3.0
necrosis (abdominal wall) 0.390
no 2,269 99.7 469 99.4






No (N=2,276) Yes (N=472)
N %Col N %Col
Enterocutaneous fistula 0.110
no 2,249 98.8 462 97.9
Yes 27 1.2 10 2.1
Biliary fluid in peritoneum 0.530
no 2,273 99.9 471 99.8
Yes 3 0.1 1 0.2
Urological injuries 1.000
no 2,266 99.6 470 99.6
Yes 10 0.4 2 0.4
Vascular injuries 0.010
no 2,272 99.8 467 98.9
Yes 4 0.2 5 1.1
neurological injuries
no 2,276 100.0 472 100.0
Yes 0 0.0 0 0.0
Other organ laceration 0.099
no 2,246 98.7 461 97.7
Yes 30 1.3 11 2.3
Vascular 0.035
no 2,166 95.2 438 92.8
Yes 110 4.8 34 7.2
Transient ischemic attack 0.530
no 2,273 99.9 471 99.8
Yes 3 0.1 1 0.2
Pulmonary embolism 0.038
no 2,274 99.9 469 99.4
Yes 2 0.1 3 0.6
angor or acute myocardial infarction 0.075
no 2,171 95.4 441 93.4
Yes 105 4.6 31 6.6
Medical complication ,0.001
no 2,141 94.1 409 86.7
Yes 135 5.9 63 13.3
Cardiac arrest ,0.001
no 2,273 99.9 465 98.5
Yes 3 0.1 7 1.5
heart failure 0.016
no 2,244 98.6 458 97.0
Yes 32 1.4 14 3.0
Kidney failure ,0.001
no 2,224 97.7 447 94.7
Yes 52 2.3 25 5.3
respiratory problems/failure ,0.001
no 2,215 97.3 438 92.8
Yes 61 2.7 34 7.2
Intestinal obstruction 0.166
no 2,254 99.0 464 98.3
Yes 22 1.0 8 1.7
Multiorgan failure 0.076
no 2,267 99.6 467 98.9
Yes 9 0.4 5 1.1
Abbreviation: %Col, column percentage.





with COPD than in those without were the dehiscence of 
the surgical wound or anastomosis, evisceration, and vas-
cular damage. The main medical complications that were 
more common in patients with COPD than in those without 
were cardiac arrest, heart failure, respiratory failure, and 
renal failure; the risk of major medical complications was 
78%–235% higher in patients with COPD (OR 2.443; 95% 
CI 1.779–3.355).
The greater incidence of complications in patients with 
COPD was also associated with greater consumption of 
resources during the hospital stay, longer LOS, and higher 
in-hospital mortality (Table 2). Greater proportions of 
patients with COPD were admitted to the ICU (31.1% vs 
23.4%; OR 1.5), received invasive mechanical ventilation 
(4.2% vs 2.4%; OR 1.8), and received antibiotics after the 
intervention (53% vs 44%; OR 1.4). Moreover, a greater 
proportion of patients with COPD required reintervention 
(11% vs 7.5%; OR 1.5). However, no differences in hemor-
rhagic complications or blood transfusions were observed 
between the two groups.
The overall mean LOS after the intervention was 
12.4±11.1 days (median 9, range 1–213). COPD was associ-
ated with longer LOS. Only 35% of the patients with COPD 
spent less than a week in hospital after the intervention 
compared to 48.5% of those without COPD. There was also 
a trend in the strength of the association between COPD 
and longer LOS, being especially strong for LOS .30 days 
(OR 2.606; 95% CI 1.715–3.959).
A total of 41 (1.5%) patients died in hospital. The risk 
of death was higher in patients with COPD (OR 5.252; 95% 
CI 2.824–9.770); after adjustment for the significant variables 
(age, sex, tumor location, ASA risk, and reintervention), the 
OR was 3.514 (95% CI 1.662–7.429) and the HR was 2.480 
(95% CI 1.228–5.006).
The survival curves (Figure 1) show that death occurred 
earlier in patients with COPD than in those without (log-
rank test 14.458; P=0.000). The most common causes of 
death in patients with COPD were septic shock and medical 
complications.
Discussion
In this nationwide study of patients undergoing surgery 
for CRC, we found that COPD was associated with higher 
rates of postoperative complications, ICU admission, 
antibiotic treatment, reinterventions, and mortality during 
hospitalization. Moreover, after adjusting for other factors, 
COPD remained clearly associated with higher and earlier 
in-hospital mortality.
Figure 1 In-hospital survival function in patients with and without COPD.
Previous nationwide studies in the USA found that even 
after adjusting for other clinical factors, COPD clearly 
increases postoperative morbidity and mortality (up to 
30 days) and LOS in patients undergoing all types of surgery 
and in patients undergoing all types of abdominal surgery.8,12 
Our results show that these findings are also valid for the 
more specific group of patients undergoing surgery for CRC 
in a nationwide sample in Spain.
The prevalence of COPD in our cohort (17%) is similar 
to that reported in other settings, although differences in 
important factors make comparisons among studies difficult. 
A previous study in our setting reported 19% prevalence of 
COPD in patients undergoing surgery for rectal cancer;13 
however, the prevalence of COPD was lower in the aforemen-
tioned studies in more general surgical populations: 5% in 
Gupta et al’s cohort and 3.8% in Fields and Divino’s cohort. 
COPD is more common in cancer patients, in part, due to 
the history of smoking habit. In our study, COPD patients 
were identified concurrently with data collection. Despite the 
difficulties inherent in this design, it does not seem that the 
prevalence of COPD has been underestimated.
The only study published to date that focuses on 
COPD in CRC interventions reported 13% 30-day 
mortality in patients with COPD, about 70% higher than 
in those without COPD; these figures varied with different 
clinical variables.9
The in-hospital mortality rate in our study was low, but 
it was four times higher in patients with COPD than in those 
without, remaining significant after adjusting for sex, age, 
ASA risk, tumor location, and reintervention. Furthermore, 
patients with COPD died earlier after the intervention, under-
lining the importance of optimizing pulmonary function when 
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possible and maintaining closer postoperative surveillance 
in these patients.
The most common causes of death in patients with COPD 
are respiratory disease and cardiovascular disease.14,15 As 
reported in other studies,16–18 the prevalence of heart failure 
and respiratory insufficiency were higher in patients with 
COPD than in those without. This clinically important dif-
ference could explain the higher rates of ICU admission 
and invasive mechanical ventilation in COPD patients. On 
the other hand, our COPD patients also had a higher rate of 
infectious complications after surgery than patients without 
COPD, which explains, in part, their higher rate of postopera-
tive antibiotic treatment. Among infectious complications, 
septic shock, pneumonia, and other respiratory tract infec-
tions were especially prevalent.
Interestingly, COPD patients in our study had higher rates 
of wound or anastomosis dehiscence, and even eviscera-
tion, partially explaining their higher rate of reintervention. 
Platon et al9 reported similar findings. The higher rates of 
these surgical complications in patients with COPD are not 
surprising: coughing is both a frequent symptom of COPD 
and a common cause of wound dehiscence; many COPD 
patients receive oral glucocorticoids that delay wound 
healing; and many lack good nutritional status essential for 
wound healing.19 All these factors explain the longer LOS 
in patients with COPD.
Conclusion
In conclusion, to reduce morbidity and mortality in patients 
with COPD undergoing surgery for CRC, several aspects 
of perioperative management are important: bronchodilator 
therapy, postoperative analgesia, and respiratory physio-
therapy should be optimized and attention should be given 
to the usual comorbidities in these patients.
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